Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

11 Jun 2014

Secondary Processing’s Effect on Fluticasone Dynamics


This research article provides an in-depth analysis of the effects of lagering conditions on the performance of Dry Powder Inhalers (DPIs). The study systematically evaluates a range of physicochemical properties under different storage conditions and time periods. The research further investigates the interfacial behavior of Fluticasone Propionate (FP) samples with various substances and compares the in vitro performance of binary and tertiary DPI formulations. The findings of this study can significantly contribute to the understanding and prediction of inter particulate forces of secondary processing of APIs in DPI systems, which is crucial for optimizing DPI product performance.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »